Vipin Garg - Altimmune President CEO, Director
| ALT Stock | USD 8.25 0.07 0.86% |
CEO
Dr. Vipin K. Garg was appointed as President, Chief Executive Officer, Director of the company effective November 30, 2018. He previously served as President and CEO of Neos Therapeutics, Inc. from October 2013 to June 2018. Prior to his service at Neos, Dr. Garg served as President and CEO of Tranzyme Pharma, Inc. from October 2001 to June 2013. Prior to joining Tranzyme, Dr. Garg served as Chief Operating Officer of Apex Bioscience, Inc., and held senior management positions at DNX BioTherapeutics, Inc. until its acquisition by Baxter Healthcare Corporationrationration, Sunovion Pharmaceuticals, Inc., and BioResponse Inc. since 2018.
| Age | 66 |
| Tenure | 6 years |
| Address | 910 Clopper Road, Gaithersburg, MD, United States, 20878 |
| Phone | 240 654 1450 |
| Web | https://altimmune.com |
Altimmune Management Efficiency
The company has Return on Asset of (0.3956) % which means that on every $100 spent on assets, it lost $0.3956. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7296) %, meaning that it generated no profit with money invested by stockholders. Altimmune's management efficiency ratios could be used to measure how well Altimmune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2024. Return On Capital Employed is likely to drop to -0.51 in 2024. Total Current Liabilities is likely to gain to about 21.2 M in 2024. Liabilities And Stockholders Equity is likely to gain to about 221.2 M in 2024Similar Executives
| Found 14 records | CEO Age | ||
| Daniel Paterson | Verastem | 63 | |
| William Sibold | Madrigal Pharmaceuticals | 58 | |
| Stephen JD | ACADIA Pharmaceuticals | 63 | |
| Cuong MBA | Biovie Inc | 58 | |
| Dr MBA | Athira Pharma | 56 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| Malte MD | Hookipa Pharma | 62 | |
| Michael Raab | Ardelyx | 59 | |
| Lisa Ricciardi | Cognition Therapeutics | 64 | |
| Brian Lian | Viking Therapeutics | 58 | |
| Andrew MD | Akero Therapeutics | 57 | |
| Catherine Adams | ACADIA Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.4 |
Altimmune Leadership Team
Elected by the shareholders, the Altimmune's board of directors comprises two types of representatives: Altimmune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Altimmune. The board's role is to monitor Altimmune's management team and ensure that shareholders' interests are well served. Altimmune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Altimmune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scot Roberts, Chief Scientific Officer | ||
| Tony BS, Vice Management | ||
| Vipin Garg, President CEO, Director | ||
| Richard MBA, Chief Officer | ||
| Kent BSEE, Co Controller | ||
| Andrew MS, Corporate Controller | ||
| Bertrand Georges, Chief Officer | ||
| Raymond MBA, Chief Officer | ||
| Jos Ochoa, Chief Officer | ||
| AGAF FCAP, Chief Officer |
Altimmune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Altimmune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 450.24 M | ||||
| Shares Outstanding | 71.12 M | ||||
| Shares Owned By Insiders | 0.79 % | ||||
| Shares Owned By Institutions | 56.67 % | ||||
| Number Of Shares Shorted | 23.43 M | ||||
| Price To Earning | (1.66) X | ||||
| Price To Book | 4.41 X | ||||
| Price To Sales | 11,284 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.